Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study

Antonio Gasbarrini, Jordi Bruix, Won-Young Tak, Armando Santoro, Massimo Colombo, Ho-Yeong Lim, Vincenzo Mazzaferro, Reiner Wiest, María Reig, Andrea Wagner, Luigi Bolondi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

154 Citazioni (Scopus)

Abstract

We assessed the safety of the multikinase inhibitor regorafenib in patients with hepatocellular carcinoma (HCC) that had progressed following first-line sorafenib.
Lingua originaleEnglish
pagine (da-a)3412-3419
Numero di pagine8
RivistaEuropean Journal of Cancer
Volume49
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • Adult
  • Aged
  • Antineoplastic Agents
  • Asia
  • Carcinoma, Hepatocellular
  • Disease Progression
  • Drug Administration Schedule
  • Europe
  • Female
  • Hepatocellular carcinoma
  • Humans
  • Kaplan-Meier Estimate
  • Liver Neoplasms
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Pyridines
  • Receptor kinase inhibition
  • Regorafenib
  • Safety
  • Second line
  • Time Factors
  • Tolerability
  • Treatment Outcome

Fingerprint

Entra nei temi di ricerca di 'Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study'. Insieme formano una fingerprint unica.

Cita questo